A circulating tumor DNA (ctDNA) test showed promise in identifying which older patients with estrogen receptor–positive ...

Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...

Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual ...

New research shows that clearing circulating tumor DNA (ctDNA) after neoadjuvant therapy strongly correlates with higher complete response rates and lower metastasis risk in triple-negative breast ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

CancerCheck is a one-of-a-kind early-detection blood test that, for the first time, can extract whole circulating tumor cells (CTCs), enabling a board-certified pathologist to deliver a ...

Please provide your email address to receive an email when new articles are posted on . Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

A new study shows that clearance of circulating tumor DNA (ctDNA) after neoadjuvant therapy strongly correlates with better pathological response and lower metastasis risk in triple-negative breast ...